ALCON INC (ALC)

Alcon is a global eye care company that researches, develops, manufactures, distributes and sells a full suite of eye care products. It was founded in 1945 as a pharmacy in Fort Worth, Texas, and was later owned by Nestlé and then Novartis. It became a stand-alone company through a spin-off from Novartis on April 9, 2019, and its shares trade on the SIX and the NYSE under the ticker "ALC." Alcon reported $9.8 billion in net sales for 2024 and says it holds the number one global market share in both the ophthalmic surgical market and the vision care market. It has grown in part through acquisitions in the past three years: BELKIN Vision (2024), Aerie Pharmaceuticals (2022) and Ivantis (2022).

The company operates two businesses. Surgical had about $5.5 billion in 2024 net sales and covers implantables, consumables and surgical equipment, plus services, for cataract, vitreoretinal, refractive laser and glaucoma procedures. Products and platforms named include the Clareon, PanOptix and Vivity intraocular lenses, the UNITY VCS and UNITY Dx equipment, the Hydrus microstent and Voyager DSLT. Vision Care had about $4.3 billion in net sales and includes daily disposable, reusable and color-enhancing contact lenses, along with ocular health products for dry eye, ocular allergies, glaucoma and contact lens care, ocular vitamins and redness relievers. Brands include TOTAL, PRECISION, Systane, Pataday and Opti-Free.

Alcon serves eye care professionals, including surgeons and optometrists, as well as consumers and patients in over 140 countries. It estimates its addressable eye care market at about $35 billion, made up of a roughly $13 billion surgical market and a roughly $22 billion vision care market. It expects the market to grow at mid-single-digit rates annually from 2024 to 2029, driven by an aging population, innovation, growth in emerging economies, and rising myopia and digital eye strain. Its field force of over 3,900 sales associates supports customers with clinical education, hands-on training, clinical data and technical service, including more than 70 interactive training centers.

Alcon employs over 25,000 associates in 56 countries and operates 17 manufacturing facilities that use proprietary technologies. More than 1,900 associates work in research and development, which received $876 million of investment in 2024; the company also pursues external innovation through acquisitions, licensing and collaborations. Its strategy centers on growing key products, accelerating innovation and expanding into adjacencies such as pharmaceuticals. Alcon AG is a Swiss corporation with its registered office in Fribourg and its headquarters in Geneva, Switzerland.